V. Recommendation of Standards for Recognition by FDA

Any person may recommend consensus standards as candidates for recognition under the new provision of section 514 of the act by submitting such recommendations, with reasons for the recommendation, to the contact person (See **FOR FURTHER INFORMATION CONTACT**). To be properly considered such recommendations should contain, at a minimum, the following information: (1) Title of the standard; (2) any reference number and date; (3) name and address of the national or international standards development organization; (4) a proposed list of devices for which a declaration of conformity to this standard should routinely apply; and (5) a brief identification of the testing or performance or other characteristics of the device(s) that would be addressed by a declaration of conformity.

VI. Electronic Access

You may obtain a copy of ''Guidance on the Recognition and Use of Consensus Standards'' by using the Internet. CDRH maintains a site on the Internet for easy access to information including text, graphics, and files that you may download to a personal computer with access to the Internet. Updated on a regular basis, the CDRH home page includes the guidance as well as the current list of recognized standards and other standards related documents. After publication in the **Federal Register**, this document announcing ''Modification to the List of Recognized Standards, Recognition List Number: 022'' will be available on the CDRH home page. You may access the CDRH home page at *http://www.fda.gov/cdrh*.

You may access ''Guidance on the Recognition and Use of Consensus Standards,'' and the searchable database for ''FDA Recognized Consensus Standards'' through the hyperlink at *http://www.fda.gov/cdrh/stdsprog.html*.

This **Federal Register** document on modifications in FDA's recognition of consensus standards is available at *http://www.fda.gov/cdrh/fedregin.html*.

VII. Submission of Comments and Effective Date

Interested persons may submit to the contact person (see **FOR FURTHER INFORMATION CONTACT**) written or electronic comments regarding this document. Two copies of any mailed comments are to be submitted, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. FDA will consider any comments received in determining whether to amend the current listing of modifications to the list of recognized standards, Recognition List Number: 022. These modifications to the list or recognized standards are effective upon publication of this document in the **Federal Register**.

Dated: August 26, 2009.

Catherine M. Cook,

Associate Director for Regulation and Policy.

[FR Doc. E9–21609 Filed 9–4–09; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention (CDC)

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Capacity Building Assistance (CBA) To Improve the Delivery and Effectiveness of Human Immunodeficiency Virus (HIV) Prevention Services for High-Risk and/or Racial/Ethnicity Minority Populations, Program Announcement Number PS09–906, Initial Review

DATES: August 28, 2009.

Correction: This notice was published in the **Federal Register** on August 6, 2009, Volume 74, Number 150, page 39333. The date on the original notice has changed.

CONTACT PERSON FOR MORE INFORMATION: Monica Farmer, M.Ed., Public Health Analyst, Strategic Science and Program Unit, Office of the Director, Coordinating Center for Infectious Diseases, CDC, 1600 Clifton Road, NE., Mailstop E–60, Atlanta, GA 30333. Telephone (404) 498–2277.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: August 25, 2009.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9–21510 Filed 9–4–09; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2009–N–0664]

2009 Parenteral Drug Association and Food and Drug Administration Joint Regulatory Conference

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

SUMMARY: The Food and Drug Administration (FDA) in co-sponsorship with the Parenteral Drug Association (PDA), is announcing a conference entitled ''Securing the Future of Medical Product Quality: A 2020 Vision.'' The workshop helps to achieve objectives set forth in the FDA Modernization Act of 1997, which include working closely with stakeholders and maximizing the availability and clarity of information to stakeholders and the public.

Date and Time: The conference will be held on Monday, September 14, 2009 from 8 a.m. to 6 p.m.; Tuesday, September 15, 2009 from 7:15 a.m. to 5:45 p.m.; and Wednesday, September 16 from 7:15 a.m. to 1:15 p.m.

Location: The public workshop will be held at the Renaissance Hotel, 999 9th St., Washington, D.C., 20001; 1–202–898–9000; FAX: 1–202–289–0947.

Contact: *Regarding the conference*: Wanda Neal, Parenteral Drug Association, PDA Global Headquarters, Bethesda Towers, 4350 East-West Hwy., suite 200, Bethesda, MD 20814.

Regarding this document: Ken Nolan, Office of External Relations, Food and Drug Administration, 5600 Fishers Lane, rm. 15–05, Rockville, MD 20857, 301–827–3376.

Registration: You are encouraged to register at your earliest convenience. The PDA registration fees cover the cost of facilities, materials, and breaks. Seats are limited; please submit your registration as soon as possible. Conference space will be filled in order of receipt of registration. Those accepted in to the conference will receive confirmation. Registration will close after applicable conference is filled. Onsite registration will be available on a space-available basis on the day of the public conference, beginning at 7 a.m. on Monday, September 14, 2009.

The cost of registration is as follows:

PDA Members	$1850.00
PDA Non-members	$2099.00
Government	$700.00
PDA Member Academic/Health Authority.	$700.00

PDA Non-Member Academic/Health Authority.	$875.00
PDA Member Students.	$200.00
Non-Member Students.	$310.00

If you need special accommodations due to a disability, please contact Wanda Neal, PDA (see *Contact*), at least 7 days in advance of the workshop.

Registration instructions: To register, please submit your name, affiliation, mailing address, phone, fax number, and e-mail, along with a check or money order payable to ''PDA.'' Mail to: PDA, Global Headquarters, Bethesda Towers, 4350 East-West Hwy., suite 200, Bethesda, MD 20814. To register via the Internet, go to the PDA Web site at *http://www.pda.org*. (FDA has verified the Web site address, but is not responsible for subsequent changes to the Web site after this document publishes in the **Federal Register**).

The registrar will also accept payment by major credit cards (VISA/MasterCard only). For more information on the meeting, or for questions on registration, contact the Parenteral Drug Association (PDA), 301–656–5900, FAX: 301–986–1093, or e-mail: *info@pda.org*.

Attendees are responsible for their own accommodations. To make reservations at the Renaissance Hotel at the reduced conference rate, contact the Renaissance Hotel (see Location), citing meeting code ''PDA.'' Room rates are: Single: $274, plus 14.5% state and local taxes; and Double: $274, plus 14.5% state and local taxes. Reservations can be made on a space and rate availability basis.

SUPPLEMENTARY INFORMATION: The PDA/FDA Joint Regulatory Conference offers the unique opportunity to join FDA representatives and industry experts in face-to-face dialogues. Each year, FDA speakers provide updates on the current state of efforts impacting the development of global regulatory strategies, while industry professionals from some of today's leading pharmaceutical companies present case studies on how they employ global strategies in their daily processes. Participants will hear directly from FDA experts and representatives of global regulatory authorities and take home best practices for compliance. The conference will span 2 1/2 days and cover current issues affecting the industry, including the following issues:

- Pharmaceutical safety and good manufacturing practices,
- Continual improvement,
- Technology transfer,
- Supply chain,
- Combination products,
- Recall root causes,
- Knowledge management,
- Good distribution practices and good importer practices, and
- Process validation and quality risk management.

The conference program will include PDA Interest Group sessions as well as an exhibition on September 14 and 15.

Immediately following the conference, on September 17 and 18, the PDA Training and Research Institute (PDA TRI) is offering courses to complement conference sessions.

FDA has made continuing education of the biologics, drug, and device manufacturing community a high priority to help ensure the quality of FDA-regulated pharmaceuticals and devices. The workshop helps to achieve objectives set forth in section 406 of the FDA Modernization Act of 1997 (21 U.S.C. 393), which include working closely with stakeholders and maximizing the availability and clarity of information to stakeholders and the public. The workshop also is consistent with the Small Business Regulatory Enforcement Fairness Act of 1996 (Public Law 104–121), as outreach activities by Government agencies to small businesses.

Dated: September 1, 2009.

David Horowitz,

Assistant Commissioner for Policy.

[FR Doc. E9–21546 Filed 9–4–09; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HOMELAND SECURITY

[Docket No. DHS–2009–0108]

Homeland Security Advisory Council

AGENCY: The Office of Policy, DHS.

ACTION: Notice of open teleconference Federal Advisory Committee meeting.

SUMMARY: The Homeland Security Advisory Council (HSAC) will meet via teleconference for the purpose of reviewing the findings and recommendations of the HSAC's Homeland Security Advisory System Task Force.

DATES: The HSAC conference call will take place from 5 p.m. to 6 p.m. EST on Tuesday, September 15, 2009. Please be advised that the meeting is scheduled for one hour and all participating members of the public should promptly call-in at the beginning of the teleconference.

ADDRESSES: The HSAC meeting will be held via teleconference. Members of the public interested in participating in this teleconference meeting may do so by following the process outlined below (*see* ''Public Attendance'').

Written comments must be submitted and received by September 12, 2009. Comments must be identified by DHS–2009–0108 and may be submitted by *one* of the following methods:

- *Federal eRulemaking Portal: http://www.regulations.gov.* Follow the instructions for submitting comments.
- *E-mail: HSAC@dhs.gov*. Include docket number in the subject line of the message.
- *Fax:* (202) 282–9207.
- *Mail:* Homeland Security Advisory Council, Department of Homeland Security, Mailstop 0850, 245 Murray Lane, SW., Washington, DC 20528.

Instructions: All submissions received must include the words ''Department of Homeland Security'' and DHS–2009—0108, the docket number for this action. Comments received will be posted without alteration at *http://www.regulations.gov,* including any personal information provided.

Docket: For access to the docket to read background documents or comments received by the DHS Homeland Security Advisory Council, go to *http://www.regulations.gov*.

FOR FURTHER INFORMATION CONTACT: HSAC Staff at *hsac@dhs.gov* or 202–447–3135.

SUPPLEMENTARY INFORMATION: Notice of this meeting is given under the Federal Advisory Committee Act, 5 U.S.C. App. 2. The HSAC provides independent advice to the Secretary of the Department of Homeland Security to aide in the creation and implementation of critical and actionable policies and capabilities across the spectrum of homeland security operations. The HSAC periodically reports, as requested, to the Secretary, on such matters. The Federal Advisory Committee Act requires **Federal Register** publication 15 days prior to a meeting. This notice is being published 11 days prior to the meeting due to the required coordination of necessary participants and changes to schedules. All known interested parties were made aware of the meetings with sufficient time for planning purposes.

The HSAC will meet to review the Homeland Security Advisory System Task Force findings and recommendations.

Public Participation: Members of the public may register to participate in this HSAC teleconference via aforementioned procedures. Each individual must provide his or her full legal name, e-mail address and phone number no later than 5 p.m. EST on